Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.35 |
| ▸ | FDPS | P14324 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8661556 | 0.92 | ALOX15 (0.75) | ALOX15ALDH1A1USP2NFE2L2EPHX2 | |
| SCHEMBL8153295 | 0.92 | ALOX15 (0.75) | ALOX15ALDH1A1USP2NFE2L2EPHX2 | |
| SCHEMBL1628643 | 0.91 | ALOX15 (0.56) | ALOX15ALDH1A1USP2NFE2L2EPHX2 | |
| SCHEMBL8660314 | 0.86 | ALOX15 (0.67) | ALOX15ALDH1A1USP2NFE2L2EPHX2 | |
| SCHEMBL11335627 | 0.85 | ALOX15 (0.75) | ALOX15ALDH1A1USP2NFE2L2EPHX2 | |
| SCHEMBL3193137 | 0.85 | ALOX15 (0.75) | ALOX15ALDH1A1USP2NFE2L2EPHX2 | |
| Crotonic Acid SCHEMBL28035376 | 0.85 | ALOX15 (0.57) | ALOX15ALDH1A1USP2NFE2L2EPHX2 | |
| SCHEMBL27967583 | 0.84 | ALOX15 (0.73) | ALOX15ALDH1A1USP2NFE2L2EPHX2 | |
| SCHEMBL30667366 | 0.83 | ALOX15 (0.71) | ALOX15ALDH1A1USP2NFE2L2EPHX2 | |
| SCHEMBL27494 | 0.83 | ALOX15 (0.71) | ALOX15ALDH1A1USP2NFE2L2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018145219-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING | SERANI MOSTAZAL JORGE (CL) | 2018-08-16 | — | — | WO | claimed |
| CN-114540123-B | Method for treating rose dregs and application thereof | 云南柏妮兰生物资源开发有限公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-110891615-B | System and method for selecting and releasing fragrance | 阿甘香气及精细化学有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-114540123-A | Method for treating rose dregs and application thereof | 云南柏妮兰生物资源开发有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-111527191-B | Encapsulated perfume compositions and methods of making same | 奇华顿股份有限公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-111527191-A | Encapsulated perfume compositions and methods of making same | 奇华顿股份有限公司 | 2020-08-11 | — | — | CN | disclosed |
| US-9959392-B2 | Olfactory signature and odorant mixture having the same | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-05-01 | — | — | US | disclosed |
| US-9890351-B2 | Encapsulates | THE PROCTER & GAMBLE COMPANY (US) | 2018-02-13 | — | — | US | disclosed |
| CN-106999972-A | System and method for discharging fragrance | 阿甘芳香和精细化工有限公司 | 2017-08-01 | — | — | CN | disclosed |
| EP-2741731-B1 | ENCAPSULATES | PROCTER & GAMBLE (US) | 2017-05-17 | — | — | EP | disclosed |
| US-20140221269-A1 | OLFACTORY SIGNATURE AND ODORANT MIXTURE HAVING THE SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2014-08-07 | — | — | US | disclosed |
| EP-2741731-A1 | ENCAPSULATES | The Procter and Gamble Company (US) | 2014-06-18 | — | — | EP | disclosed |
| US-8539631-B2 | Roller for providing benefits to fabric | THE PROCTER & GAMBLE COMPANY (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2468239-B1 | Encapsulates | PROCTER & GAMBLE INTERNAT OPERATIONS SA (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20130039962-A1 | ENCAPSULATES | ENCAPSYS, LLC | 2013-02-14 | — | — | US | disclosed |
| WO-2013022949-A1 | ENCAPSULATES | THE PROCTER & GAMBLE COMPANY (US) | 2013-02-14 | — | — | WO | disclosed |
| EP-2468239-A1 | Encapsulates | Procter & Gamble International Operations SA (CH) | 2012-06-27 | — | — | EP | disclosed |
| EP-1765139-A1 | ROLLER FOR PROVIDING BENEFITS TO FABRIC | The Procter and Gamble Company (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006010087-A1 | ROLLER FOR PROVIDING BENEFITS TO FABRIC | THE PROCTER & GAMBLE COMPANY (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060005333-A1 | Roller for providing benefits to fabric | PROCTER & GAMBLE COMPANY, THE | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130039962-A1 | ENCAPSULATES | ABCB4, PPIB, FLNB | ALOX15 433/4885ALDH1A1 696/4885USP2 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.